Fintel reports that on September 19, 2023, Cantor Fitzgerald reiterated coverage of Rezolute (NASDAQ:RZLT) with a Overweight recommendation.
Analyst Price Forecast Suggests 433.96% Upside
As of August 31, 2023, the average one-year price target for Rezolute is 7.96. The forecasts range from a low of 4.04 to a high of $14.70. The average price target represents an increase of 433.96% from its latest reported closing price of 1.49.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Rezolute is 0MM. The projected annual non-GAAP EPS is -1.51.
What is the Fund Sentiment?
There are 46 funds or institutions reporting positions in Rezolute. This is a decrease of 3 owner(s) or 6.12% in the last quarter. Average portfolio weight of all funds dedicated to RZLT is 0.29%, an increase of 20.65%. Total shares owned by institutions decreased in the last three months by 5.51% to 24,241K shares.
What are Other Shareholders Doing?
Federated Hermes holds 6,610K shares representing 17.95% ownership of the company. No change in the last quarter.
First Manhattan holds 3,623K shares representing 9.84% ownership of the company. In it's prior filing, the firm reported owning 3,123K shares, representing an increase of 13.80%. The firm increased its portfolio allocation in RZLT by 14.27% over the last quarter.
FKASX - Federated Kaufmann Small Cap Fund Shares holds 3,311K shares representing 8.99% ownership of the company. No change in the last quarter.
KAUAX - Federated Kaufmann Fund Shares holds 3,215K shares representing 8.73% ownership of the company. No change in the last quarter.
Stonepine Capital Management holds 3,072K shares representing 8.34% ownership of the company. In it's prior filing, the firm reported owning 3,088K shares, representing a decrease of 0.49%. The firm increased its portfolio allocation in RZLT by 14.95% over the last quarter.
Rezolute Background Information
(This description is provided by the company.)
Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric endocrine disorder. Its pipeline also includes RZ402, an IND-ready orally available plasma kallikrein inhibitor, which is staged to transition into clinical development for the treatment of diabetic macular edema.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
